Atorvastatin and almonertinib-induced myopathy in a polypharmacy context: a case report - Takeaways - MDSpire

Atorvastatin and almonertinib-induced myopathy in a polypharmacy context: a case report

  • By

  • Jifang Zhou

  • Lixia Yu

  • Huimin Xu

  • May 14, 2026

Share

  • 1

    Statin-induced myopathy is a common adverse effect, especially when combined with CYP3A4 inhibitors like almonertinib.

  • 2

    An 89-year-old male patient developed myopathy after starting atorvastatin while on almonertinib, evidenced by elevated CK levels.

  • 3

    Discontinuation of atorvastatin and almonertinib led to normalization of the patient's CK levels.

  • 4

    Almonertinib is a moderately sensitive substrate of CYP3A4, increasing the risk of statin-related myopathy.

  • 5

    Alternative cholesterol-lowering medications like PCSK9 inhibitors should be considered for patients on almonertinib.

Original Source(s)

Atorvastatin and almonertinib-induced myopathy in a polypharmacy context: a case report

  • by Jifang Zhou, Lixia Yu, Huimin Xu

  • May 14, 2026

Related Content

LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload

Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on...

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...

Mass Spec Roundup: Proteins, Lipids, Pitcher Plants, and Coffee

This week’s roundup explores hidden chemistry in the dark proteome, forest soils, lipid binding in cells, and pitcher plant food webs

  • May 13, 2026

  • 7 min